12:00 AM
 | 
Dec 24, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Jakafi ruxolitinib regulatory update

Germany's Institute for Quality and Efficiency in Health Care (IQWiG) and Novartis both estimate that Orphan drug Jakavi ruxolitinib will cost the German statutory health insurance funds (GKV) more than €50 million per year. Thus, the myelofibrosis drug is likely...

Read the full 178 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >